BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, January 29, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2010

View Archived Issues

Clinical development of ChimeriVax-Dengue vaccine updated

Read More

EVX-001650 displays antipsychotic activity in mouse models related to schizophrenia

Read More

AC-430 confers protection in models of autoimmune and inflammatory conditions

Read More

Proof-of-concept secukinumab trial in ankylosing spondylitis meets primary endpoint

Read More

Exelixis divulges novel mTORC1 inhibitors

Read More

Aveo Pharma advances phase Ib tivozanib/capecitabine combination trial

Read More

Orban Biotech receives Qualifying Therapeutic Discovery grant for IBC-VS01 vaccine

Read More

Salvat licenses tarafenacin to Kwang Dong Pharma for OAB in South Korea

Read More

Morphotek and Hokkaido University join to evaluate amatuximab for pancreatic cancer

Read More

Decreased IGF-I levels may correlate with growth defects in newborns with cystic fibrosis

Read More

Bristol-Myers Squibb updates pipeline progress for Q3 of 2010

Read More

Ipsen Pharma identifies new imidazolidine-2,4-dione derivatives for prostate cancer

Read More

Banyu Pharma presents new peptide P518 receptor antagonists

Read More

Lumixex launches diagnostic xTAG CYP2D6 Kit in U.S.

Read More

Circassia's Toleromune House Dust Mite vaccine shows promise in phase II trial

Read More

Genzyme to sell diagnostics business to Sekisui Chemical

Read More

Astex Therapeutics claims new fibroblast growth factor receptor inhibitors

Read More

Errant Gene Therapeutics receives U.S. federal grant for Thalagen research

Read More

Advanced Life Sciences applies for FDA orphan drug status for ALS-886 in ARDS

Read More

Phytopharm advances phase II smilagenin trial in early-stage Parkinson's disease

Read More

New GlyT-1 inhibitors claimed by sanofi-aventis

Read More

Phase III APPRAISE-2 trial of apixaban in ACS discontinued

Read More

Reolysin to enter phase I trial in pediatric patients with solid tumors

Read More

FDA approves Xgeva for SRE prophylaxis in patients with bone metastases from solid tumors

Read More

Second interim RESTORE-CLI data analysis shows primary endpoints met

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 28, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 28, 2026.
  • DNA mutations or genetic disorder concept art

    Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

    BioWorld Science

    Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Dice spelling out D-E-A-L-?, yes, no

    Muted and missing M&As: JPM deals absent in 2026

    BioWorld
    For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing